Skip to main content
Terug
SSMXY logo

Sysmex Corporation

Datakwaliteit: 100%
SSMXY
OTC Healthcare Medical - Instruments & Supplies
€ 8,53
▲ € 0,17 (2,03%)
Marktkapitalisatie: 5,32B
Ook genoteerd als SSMXF OTC
Dagbereik
€ 8,50 € 8,55
52-Weeksbereik
€ 8,15 € 19,65
Volume
9.783
50D / 200D Gem.
€ 9,30 / € 12,08
Vorige Slotkoers
€ 8,36

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 0,1 0,4
P/B 0,0 2,9
ROE % 12,0 3,7
Net Margin % 10,6 3,8
Rev Growth 5Y % 13,6 10,0
D/E 0,1 0,2

Belangrijkste Punten

Revenue grew 13,63% annually over 5 years — strong growth
ROE of 11,98% — decent returns on equity
Debt/Equity of 0,14 — conservative balance sheet
Generating 38,29B in free cash flow
P/E of 0,10 — trading at a low valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 3,42%

Groei

Revenue Growth (5Y)
13,63%
Revenue (1Y)10,21%
Earnings (1Y)8,12%
FCF Growth (3Y)22,09%

Kwaliteit

Return on Equity
11,98%
ROIC12,43%
Net Margin10,55%
Op. Margin17,22%

Veiligheid

Debt / Equity
0,14
Current Ratio2,97
Interest Coverage24,90

Waardering

P/E Ratio
0,10
P/B Ratio0,01
EV/EBITDA-0,22
Dividend Yield0,01%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 10,21% Revenue Growth (3Y) 11,31%
Earnings Growth (1Y) 8,12% Earnings Growth (3Y) 8,27%
Revenue Growth (5Y) 13,63% Earnings Growth (5Y) 13,89%
Profitability
Revenue (TTM) 508,64B Net Income (TTM) 53,67B
ROE 11,98% ROA 8,07%
Gross Margin 53,47% Operating Margin 17,22%
Net Margin 10,55% Free Cash Flow (TTM) 38,29B
ROIC 12,43% FCF Growth (3Y) 22,09%
Safety
Debt / Equity 0,14 Current Ratio 2,97
Interest Coverage 24,90 Dividend Yield 0,01%
Valuation
P/E Ratio 0,10 P/B Ratio 0,01
P/S Ratio 0,01 PEG Ratio 3,85
EV/EBITDA -0,22 Dividend Yield 0,01%
Market Cap 5,32B Enterprise Value -19,52B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 508,64B 461,51B 410,50B 363,78B 305,07B
Net Income 53,67B 49,64B 45,78B 44,09B 31,90B
EPS (Diluted) 86,05 79,24 72,91 70,16 50,82
Gross Profit 271,98B 242,50B 216,08B 190,59B 154,30B
Operating Income 87,58B 78,38B 72,65B 69,57B 50,95B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 665,27B 618,92B 531,07B 483,71B 424,90B
Total Liabilities 200,73B 186,02B 142,72B 134,90B 118,96B
Shareholders' Equity 463,78B 432,05B 387,67B 348,30B 307,90B
Total Debt 64,74B 55,34B 22,59B 22,28B 21,96B
Cash & Equivalents 89,57B 75,51B 69,46B 73,75B 66,47B
Current Assets 364,82B 343,46B 295,49B 275,09B 230,83B
Current Liabilities 122,83B 118,08B 111,10B 102,08B 89,91B

Strategiescores

This stock passed the criteria for 3 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Deep Value Investing (Seth Klarman)
#256 of 820
53
Growth Price/Sales Ratio Focus (Ken Fisher)
#557 of 616
10
Value Defensive Investing (Benjamin Graham)
#470 of 708
20

Recente Activiteit

Ingestapt Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026